ArticleAmerican journal of translational research2022
Inclusion complex of lurasidone hydrochloride with Sulfobutylether-β-cyclodextrin has enhanced oral bioavailability and no food effect.
Article in American journal of translational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 6 citations in OpenAlex.
- Functional Liposomes Improve the Oral Absorption of Lurasidone Hydrochloride by Overcoming Multiple Absorption Barriers and Eliminating Food Effect.International journal of nanomedicine · 2025Article
- Sulfo-butyl ether β-cyclodextrin inclusion complexes of bosutinib: in silico, in vitro and in vivo evaluation in attenuating the fast-fed variability.Drug delivery and translational research · 2024Article
- Enhanced oral delivery of hesperidin-loaded sulfobutylether-β-cyclodextrin/chitosan nanoparticles for augmenting its hypoglycemic activity: in vitro-in vivo assessment study.Drug delivery and translational research · 2024Article
- In Vitro Assessment of Compounded Lurasidone Suspensions for Enteral Feeding Tubes.Hospital pharmacy · 2023Article
- Fast-Fed Variability: Insights into Drug Delivery, Molecular Manifestations, and Regulatory Aspects.Pharmaceutics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to improve the solubility in water and bioavailability
methodsThe saturated aqueous solution method was used to prepare an inclusion complex of LUR with sulfobutylether-β-cyclodextrin, or SBE-β-CD (LUR-SBE-β-CD). A single-factor test was used for the preliminary screening of important preparing conditions including the ethanol concentration, the SBE-β-CD concentration, temperature, and pH. Then central composite design response surface methodology (CCD) was adopted for the optimum craft. Differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), and powder X-ray diffraction (PXRD) were used to confirm the formation of LUR-SBE-β-CD. The
resultsThe dissolution studies revealed that the dissolution of LUR in LUR-SBE-β-CD was much improved in the four media and simulated gastrointestinal fluid. Similar profiles of LUR-SBE-β-CD were obtained in pharmacokinetic studies whether beagle dogs took food or not.
conclusionsThe bioavailability of LUR can be improved and the food effect can be eliminated by LUR-SBE-β-CD.
Indexed as
Identifiers
35422944PMC8991155W4226378136What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.